Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02712905 · ClinicalTrials.gov registry record · Phase 1
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT02712905 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 116 participants.
The verdict
NCT02712905, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 (dose expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the selected monotherapy dose(s) in AML/MDS, SCLC, myelofibrosis, Ewing sarcoma, and poorly differentiated neuroendocrine tumors. Part 3 will determine the recommended dose(s) of INCB059872 in combination with azacitadine and all-trans retinoic acid in AML and in combination with nivolumab in SCLC. Part 4 will further determine the safety, tolerability, efficacy, PK, and PD of the selected combination dose(s) in Part 3.
Interventions
- DRUG azacitidine
- DRUG nivolumab
- DRUG INCB059872
- DRUG all-trans retinoic acid (ATRA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2016-05-05 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02712905
The ClinicalTrials.gov registry entry for NCT02712905 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which azacitidine is the first listed.
NCT02712905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02712905 about?
NCT02712905 is a clinical study titled "An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies". This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and...
What is the current status of trial NCT02712905?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2016-05-05. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT02712905?
The interventions under investigation include: azacitidine (DRUG), nivolumab (DRUG), INCB059872 (DRUG), all-trans retinoic acid (ATRA) (DRUG).
Who is sponsoring clinical trial NCT02712905?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.